Literature DB >> 3730735

Bone loss in rheumatoid arthritis and primary generalized osteoarthrosis: effects of corticosteroids, suppressive antirheumatic drugs and calcium supplements.

D M Reid, N S Kennedy, M A Smith, J Nicoll, N Brown, P Tothill, G Nuki.   

Abstract

The annual rate of bone loss in rheumatoid arthritis (RA) and primary generalized osteoarthrosis (PGOA) was determined by measurement of total body calcium (TBCa). The mean annual rate of bone loss in 24 patients with RA treated with nonsteroidal anti-inflammatory drugs (NSAIDs) alone was 3.4%. This rate of bone loss was not reduced in ten RA patients responding to suppressive antirheumatic drugs (4.3%) or seven patients receiving oral calcium supplements (4.5%). The mean annual rate of loss of TBCa in 19 patients with PGOA was 1.6%, a figure which probably represents age-associated bone loss. The rate of bone loss in PGOA was significantly less than that in RA patients not receiving corticosteroids. The mean annual rate of change of TBCa in 30 RA patients receiving corticosteroids (+0.7%) was significantly less than that in any of the other RA groups despite an initial normalized bone mass which was significantly less than in those RA patients receiving NSAIDs alone. The data supported the hypothesis that bone loss occurred early in the course of corticosteroid therapy and thereafter the drugs might have a protective effect on the loss of bone in RA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3730735     DOI: 10.1093/rheumatology/25.3.253

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  11 in total

Review 1.  Bone mass in patients with rheumatoid arthritis.

Authors:  R F Laan; P L van Riel; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

2.  Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage.

Authors:  Mona Helmy Abdel Meguid; Yousry Hasan Hamad; Rania Shafek Swilam; Mohamed Samy Barakat
Journal:  Rheumatol Int       Date:  2012-04-25       Impact factor: 2.631

3.  Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica.

Authors:  D M Reid; J J Nicoll; M A Smith; B Higgins; P Tothill; G Nuki
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

4.  Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x ray absorptiometry.

Authors:  V B Dhillon; M C Davies; M L Hall; J M Round; P J Ell; H S Jacobs; M L Snaith; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1990-08       Impact factor: 19.103

5.  Assessment of phalangeal bone loss in patients with rheumatoid arthritis by quantitative ultrasound.

Authors:  P Röben; R Barkmann; S Ullrich; A Gause; M Heller; C C Glüer
Journal:  Ann Rheum Dis       Date:  2001-07       Impact factor: 19.103

6.  Treatment of osteoporosis of rheumatoid arthritis.

Authors:  F P Cantatore; M Carrozzo
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

7.  Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort.

Authors:  M R Krogsgaard; G Thamsborg; B Lund
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

8.  Serum osteocalcin as an index of bone turnover in active rheumatoid arthritis and in active psoriatic arthritis.

Authors:  M Magarò; L Altomonte; L Mirone; A Zoli; A Tricerri
Journal:  Clin Rheumatol       Date:  1989-12       Impact factor: 2.980

9.  Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study.

Authors:  H Kröger; R Honkanen; S Saarikoski; E Alhava
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

10.  Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis.

Authors:  N F Peel; D J Moore; N A Barrington; D E Bax; R Eastell
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.